Mounjaro Savings & Cost Guide (2026)
Mounjaro is FDA-approved for type 2 diabetes. List price is $1,112.16 per month; commercial insurance brings it as low as $25/mo with the Savings Card. Verified monthly.
Mounjaro (tirzepatide) is Eli Lilly's FDA-approved GLP-1 for adults and children aged 10 and older with type 2 diabetes. List price is $1,112.16 per 28-day supply. With commercial insurance covering Mounjaro for diabetes, the Mounjaro Savings Card brings out-of-pocket cost as low as $25 per month. Patients with commercial insurance whose plan does not cover Mounjaro pay as low as $499 per month with the same card. Federal insurance programs (Medicare, Medicaid, Tricare, VA) are excluded from the card by law. If you are seeking tirzepatide for weight loss rather than diabetes, Zepbound is the FDA-approved option and has a cash-pay path ($299-$449 per month) that Mounjaro does not.
Looking for tirzepatide for weight loss? Use Zepbound, not Mounjaro.
Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. The difference is FDA approval: Mounjaro is approved for type 2 diabetes, Zepbound is approved for weight loss. Insurance rarely covers Mounjaro for off-label weight loss, forcing patients to pay $995+ per month retail. Zepbound offers a LillyDirect Self Pay program at $299-$449/month, which Mounjaro does not. If your goal is weight loss, talk to your prescriber about Zepbound instead.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide when prescribed for type 2 diabetes. It is a once-weekly subcutaneous injection activating both GLP-1 and GIP receptors. FDA-approved for type 2 diabetes in adults and children aged 10 and older.
Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. The difference is FDA indication, which changes what insurance covers and which savings programs you can use.
Pricing snapshot
As low as $25/mo with commercial insurance that covers Mounjaro for diabetes, up to $1,112.16/mo at list price.
Explore the guide
Two dedicated pages cover the Savings Card and the monthly cost breakdown.
Recent pricing news
Federal pricing framework and list-price updates in 2025 and 2026.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Trump administration struck a deal with Eli Lilly and Novo Nordisk to lower GLP-1 prices. Impact for Mounjaro: Medicare price expected at approximately $245/month, with copays capped around $50/month for eligible beneficiaries. Coverage expected to roll out middle of 2026. TrumpRx direct-to-consumer platform launching early 2026 with GLP-1s at approximately $350/month.
Status: Announced and in implementation. Medicare and Medicaid pricing rules updating through 2026.
- January 1, 2026
List price increase to $1,112.16
Lilly updated the WAC list price for Mounjaro from $1,069.08 to $1,112.16 per 28-day supply as of January 1, 2026. This is the manufacturer wholesale price, not the patient out-of-pocket cost.
Frequently asked
Top questions about Mounjaro access and cost. Full FAQ on the coupon page.
Compare with other GLP-1s
Pricing verified against Eli Lilly's official pricinginfo.lilly.com and mounjaro.lilly.com pages, cross-referenced with GoodRx, Noom, Drugs.com, and AARP reporting. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.